Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Oct;70(4):646–651. doi: 10.1038/bjc.1994.365

Neutralising antibodies in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b.

J B Bell 1, R Barfoot 1, T Iveson 1, R L Powles 1, B C Millar 1
PMCID: PMC2033398  PMID: 7917911

Abstract

In a study of 29 patients who were receiving or had received interferon alpha 2b (IFN-alpha 2b) as maintenance therapy for multiple myeloma, antibodies were detected in 58% (17/29) of patients measured by a solid-phase enzyme-linked immunosorbent assay (ELISA). Only 7/17 patients who were positive for antibody in the ELISA had neutralising antibody to IFN-alpha 2b, measured by virus growth inhibition. These patients comprised six who were receiving IFN-alpha 2b at the time of assessment and one who had finished treatment. Among patients who were receiving the cytokine, four had progressive disease, one was in complete remission and one in partial remission. Neutralising activity was also detected to natural human leucocyte IFN-alpha in the same patients. Two patients who were positive for neutralising antibody remain in remission and are continuing to receive IFN-alpha 2b. These two patients have since lost their neutralising titre. No neutralising antibody to IFN-alpha 2b or natural human leucocyte IFN-alpha was detected in serum from six normal donors. The data suggest that neutralising antibody formation in patients with multiple myeloma is not responsible for relapse in patients receiving IFN-alpha 2b. The transient nature of neutralising antibody production in patients who remain in remission suggests that this response to IFN-alpha 2b is not associated with memory B cells.

Full text

PDF
646

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aapro M. S., Alberts D. S., Salmon S. E. Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol. 1983;10(3):161–166. doi: 10.1007/BF00255753. [DOI] [PubMed] [Google Scholar]
  2. Attal M., Huguet F., Schlaifer D., Payen C., Laroche M., Fournie B., Mazieres B., Pris J., Laurent G. Intensive combined therapy for previously untreated aggressive myeloma. Blood. 1992 Mar 1;79(5):1130–1136. [PubMed] [Google Scholar]
  3. Costanzi J. J., Cooper M. R., Scarffe J. H., Ozer H., Grubbs S. S., Ferraresi R. W., Pollard R. B., Spiegel R. J. Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma. J Clin Oncol. 1985 May;3(5):654–659. doi: 10.1200/JCO.1985.3.5.654. [DOI] [PubMed] [Google Scholar]
  4. Figlin R. A., Itri L. M. Anti-interferon antibodies: a perspective. Semin Hematol. 1988 Jul;25(3 Suppl 3):9–15. [PubMed] [Google Scholar]
  5. Freund M., von Wussow P., Diedrich H., Eisert R., Link H., Wilke H., Buchholz F., LeBlanc S., Fonatsch C., Deicher H. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol. 1989 Jul;72(3):350–356. doi: 10.1111/j.1365-2141.1989.tb07715.x. [DOI] [PubMed] [Google Scholar]
  6. Freund M., von Wussow P., Knüver-Hopf J., Mohr H., Pohl U., Exeriede G., Link H., Wilke H. J., Poliwoda H. Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b. Blut. 1988 Nov;57(5):311–315. doi: 10.1007/BF00320360. [DOI] [PubMed] [Google Scholar]
  7. Geysen H. M., Mason T. J., Rodda S. J. Cognitive features of continuous antigenic determinants. J Mol Recognit. 1988 Feb;1(1):32–41. doi: 10.1002/jmr.300010107. [DOI] [PubMed] [Google Scholar]
  8. Gutterman J. U., Blumenschein G. R., Alexanian R., Yap H. Y., Buzdar A. U., Cabanillas F., Hortobagyi G. N., Hersh E. M., Rasmussen S. L., Harmon M. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med. 1980 Sep;93(3):399–406. doi: 10.7326/0003-4819-93-3-399. [DOI] [PubMed] [Google Scholar]
  9. Itri L. M., Campion M., Dennin R. A., Palleroni A. V., Gutterman J. U., Groopman J. E., Trown P. W. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection. Cancer. 1987 Feb 1;59(3 Suppl):668–674. doi: 10.1002/1097-0142(19870201)59:3+<668::aid-cncr2820591317>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  10. Konrad M. W., Childs A. L., Merigan T. C., Borden E. C. Assessment of the antigenic response in humans to a recombinant mutant interferon beta. J Clin Immunol. 1987 Sep;7(5):365–375. doi: 10.1007/BF00917014. [DOI] [PubMed] [Google Scholar]
  11. Leavitt R. D., Ratanatharathorn V., Ozer H., Ultmann J. E., Portlock C., Myers J. W., Kisner D., Norred S., Spiegel R. J., Bonnem E. M. Alfa-2b interferon in the treatment of Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol. 1987 Jun;14(2 Suppl 2):18–23. [PubMed] [Google Scholar]
  12. Ludwig H., Cohen A. M., Huber H., Nachbaur D., Jungi W. F., Senn H., Günczler P., Schüller J., Eckhardt S., Seewann H. L. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results. Eur J Cancer. 1991;27 (Suppl 4):S40–S45. doi: 10.1016/0277-5379(91)90570-4. [DOI] [PubMed] [Google Scholar]
  13. Mellstedt H., Ahre A., Björkholm M., Holm G., Johansson B., Strander H. Interferon therapy in myelomatosis. Lancet. 1979 Feb 3;1(8110):245–247. doi: 10.1016/s0140-6736(79)90770-0. [DOI] [PubMed] [Google Scholar]
  14. Millar B. C., Bell J. B., Lakhani A., Ayliffe M. J., Selby P. J., McElwain T. J. A simple method for culturing myeloma cells from human bone marrow aspirates and peripheral blood in vitro. Br J Haematol. 1988 Jun;69(2):197–203. doi: 10.1111/j.1365-2141.1988.tb07622.x. [DOI] [PubMed] [Google Scholar]
  15. Palumbo A., Boccadoro M., Garino L. A., Gallone G., Frieri R., Pileri A. Multiple myeloma: intensified maintenance therapy with recombinant interferon-alpha-2b plus glucocorticoids. Eur J Haematol. 1992 Aug;49(2):93–97. doi: 10.1111/j.1600-0609.1992.tb00037.x. [DOI] [PubMed] [Google Scholar]
  16. Ross C., Hansen M. B., Schyberg T., Berg K. Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors. Clin Exp Immunol. 1990 Oct;82(1):57–62. doi: 10.1111/j.1365-2249.1990.tb05403.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ruiz-Argüelles G. J., Katzmann J. A., Greipp P. R., Gonchoroff N. J., Garton J. P., Kyle R. A. Multiple myeloma: circulating lymphocytes that express plasma cell antigens. Blood. 1984 Aug;64(2):352–356. [PubMed] [Google Scholar]
  18. Rödjer S., Vikrot O., Wahlin A., Westin J. Effect of interferon alpha-2b in advanced multiple myeloma. J Intern Med. 1990 Jan;227(1):45–48. doi: 10.1111/j.1365-2796.1990.tb00117.x. [DOI] [PubMed] [Google Scholar]
  19. Salmon S. E., Beckord J., Pugh R. P., Barlogie B., Crowley J. alpha-Interferon for remission maintenance: preliminary report on the Southwest Oncology Group Study. Semin Oncol. 1991 Oct;18(5 Suppl 7):33–36. [PubMed] [Google Scholar]
  20. Spiegel R. J., Spicehandler J. R., Jacobs S. L., Oden E. M. Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A). Am J Med. 1986 Feb;80(2):223–228. doi: 10.1016/0002-9343(86)90013-6. [DOI] [PubMed] [Google Scholar]
  21. Steinmann G. G., Göd B., Rosenkaimer F., Adolf G., Bidlingmaier G., Frühbeis B., Lamche H., Lindner J., Patzelt E., Schmähling C. Low incidence of antibody formation due to long-term interferon-alpha 2c treatment of cancer patients. Clin Investig. 1992 Feb;70(2):136–141. doi: 10.1007/BF00227355. [DOI] [PubMed] [Google Scholar]
  22. Steis R. G., Smith J. W., 2nd, Urba W. J., Clark J. W., Itri L. M., Evans L. M., Schoenberger C., Longo D. L. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med. 1988 Jun 2;318(22):1409–1413. doi: 10.1056/NEJM198806023182201. [DOI] [PubMed] [Google Scholar]
  23. Steis R. G., Smith J. W., 2nd, Urba W. J., Venzon D. J., Longo D. L., Barney R., Evans L. M., Itri L. M., Ewel C. H. Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia. Blood. 1991 Feb 15;77(4):792–798. [PubMed] [Google Scholar]
  24. Trown P. W., Kramer M. J., Dennin R. A., Jr, Connell E. V., Palleroni A. V., Quesada J., Gutterman J. U. Antibodies to human leucocyte interferons in cancer patients. Lancet. 1983 Jan 15;1(8316):81–84. doi: 10.1016/s0140-6736(83)91737-3. [DOI] [PubMed] [Google Scholar]
  25. Umeda M., Shirai T., Tsukahara T., Kaneko H., Yamauchi M., Arai N., Kosuge T., Kato M., Shikoshi K., Anno S. [Clinical trial of alpha-interferon (human lymphoblastoid interferon) in combination with VCAP chemotherapy in multiple myeloma]. Rinsho Ketsueki. 1991 Jun;32(6):669–674. [PubMed] [Google Scholar]
  26. Westin J., Cortelezzi A., Hjorth M., Rödjer S., Turesson I., Zador G. Interferon therapy during the plateau phase of multiple myeloma: an update of the Swedish study. Eur J Cancer. 1991;27 (Suppl 4):S45–S48. doi: 10.1016/0277-5379(91)90571-t. [DOI] [PubMed] [Google Scholar]
  27. von Wussow P., Freund M., Block B., Diedrich H., Poliwoda H., Deicher H. Clinical significance of anti-IFN-alpha antibody titres during interferon therapy. Lancet. 1987 Sep 12;2(8559):635–636. doi: 10.1016/s0140-6736(87)93034-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES